세계의 전이성 대장암 치료제 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 약제 클래스별, 유통 채널별, 지역별, 경쟁별(2020-2030년)
Metastatic Colorectal Cancer Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Distribution Channel By Region and Competition, 2020-2030F
상품코드:1697999
리서치사:TechSci Research
발행일:2025년 03월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
전이성 대장암 치료제 세계 시장 규모는 2024년 34억 달러로 평가되었고, 2030년까지 예측 기간 동안 4.45%의 연평균 복합 성장률(CAGR)로 꾸준히 성장할 것으로 예상됩니다.
세계 전이성 대장암 치료제 시장은 광범위한 암 분야 제약 산업에서 역동적이고 중요한 부문입니다. 전이성 대장암 치료제(mCRC)는 결장이나 직장에서 다른 신체 부위, 특히 간이나 폐로 암세포가 전이되는 치명적인 질환입니다. 이 시장은 치료 접근법, 진단 방법, 치료제의 끊임없는 혁신이 특징이며, 환자의 결과와 전체 생존율을 개선하기 위해 노력하고 있습니다. 이 시장의 성장 촉진요인 중 하나는 전 세계적으로 대장암 발병률이 증가하고 있으며, 특히 고령화가 진행 중인 선진국의 경우, 대장암 발병률이 증가하고 있다는 점입니다. 조기 진단과 표적치료, 면역요법, 병용요법의 발전은 mCRC의 관리에 혁명을 가져왔으며, 효과적이고 맞춤 치료 옵션에 대한 수요가 증가하고 있습니다. 제약사들은 이 분야의 연구개발의 최전선에 있으며, 임상시험과 신약개발에 많은 투자를 통해 효능이 우수하고 부작용이 적은 새로운 치료법을 도입하기 위해 노력하고 있습니다. 단클론항체, 티로신 키나아제 억제제, 면역요법 등은 mCRC 치료에 있어 주목받고 있는 혁신적인 접근법 중 일부입니다.
Global Metastatic Colorectal Cancer Drugs Market was valued at USD 3.40 Billion in 2024 and is anticipated to project steady growth in the forecast period with a CAGR of 4.45% through 2030. The Global Metastatic Colorectal Cancer Drugs Market represents a dynamic and critical segment within the broader oncology pharmaceutical industry. Metastatic Colorectal Cancer Drugs (mCRC) is a devastating condition characterized by the spread of cancerous cells from the colon or rectum to other parts of the body, most commonly the liver and lungs. This market is marked by constant innovation in treatment approaches, diagnostic methods, and therapeutic agents, as it strives to improve patient outcomes and overall survival rates. One of the key drivers of growth in this market is the rising incidence of colorectal cancer worldwide, particularly in developed nations with aging populations. Early diagnosis and advancements in targeted therapies, immunotherapies, and combination treatments have revolutionized the management of mCRC, leading to increased demand for effective and personalized treatment options. Pharmaceutical companies are at the forefront of research and development in this space, investing heavily in clinical trials and drug discovery to introduce novel therapies with improved efficacy and fewer side effects. Monoclonal antibodies, tyrosine kinase inhibitors, and immunotherapies are some of the innovative approaches that have gained prominence in the treatment of mCRC.
Rising Incidence of Colorectal Cancer & Aging Population
The rising global incidence of colorectal cancer (CRC) is a primary driver of the Global Metastatic Colorectal Cancer (mCRC) Drugs Market. In 2020, the global colorectal cancer burden was significant, with an estimated 1.9 million newly diagnosed cases and over 930,000 fatalities attributed to the disease. These figures underscore the increasing prevalence and mortality rate of colorectal cancer, highlighting the urgent demand for advanced treatment solutions and expanded healthcare interventions in both developed and emerging markets. As the number of diagnosed cases continues to escalate, the demand for advanced treatment options, innovative drug therapies, and improved patient care solutions is rising. This trend is creating significant business opportunities for pharmaceutical companies, biotech firms, and healthcare providers.
Key Market Challenges
Late-stage Diagnosis
Metastatic Colorectal Cancer Drugs begins as colorectal cancer but progresses to a stage where cancer cells have spread to other parts of the body, such as the liver, lungs, or distant lymph nodes. The problem often starts with late-stage diagnosis, where patients do not exhibit symptoms until the disease has already advanced.
Several factors contribute to the late-stage diagnosis of mCRC. One key factor is the lack of routine screening and awareness. Unlike breast or prostate cancer, colorectal cancer lacks widespread routine screening programs, leading to delayed detection. Moreover, some individuals may avoid seeking medical attention due to embarrassment or fear of invasive procedures associated with colorectal cancer screening. Healthcare disparities also play a role in late-stage diagnosis. Limited access to healthcare services, especially in underserved communities or low-income regions, can lead to delayed diagnosis and treatment initiation. Additionally, healthcare providers may not always consider colorectal cancer as a potential diagnosis, leading to misdiagnoses or delayed referrals to specialists.
Key Market Trends
Advancements in Immunotherapy
Advancements in immunotherapy have emerged as a potent force in the global Metastatic Colorectal Cancer Drugs (mCRC) market, ushering in a new era of hope and promise for patients facing this challenging disease. Immunotherapy, a groundbreaking treatment approach that harnesses the body's own immune system to target and destroy cancer cells, has begun to revolutionize the treatment landscape for mCRC.
Key immunotherapeutic agents, such as immune checkpoint inhibitors, have demonstrated remarkable efficacy in specific subsets of mCRC patients. Pembrolizumab and nivolumab, for instance, have gained FDA approval for mCRC patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) tumors. These therapies have shown the potential to induce long-lasting responses, providing new treatment options for a previously underserved patient population.
Key Market Players
Amgen Inc.
EMD Serono
Eli Lilly and company
Genentech Inc.
Novartis AG
Pfizer Inc.
F. Hoffmann-La Roche Ltd
Sanofi
Suzhou Zelgen Biopharmaceuticals
Taiho Oncology
Report Scope:
In this report, the Global Metastatic Colorectal Cancer Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Metastatic Colorectal Cancer Drugs Market, By Drug Class:
Metastatic Colorectal Cancer Drugs Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Metastatic Colorectal Cancer Drugs Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Egypt
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Metastatic Colorectal Cancer Drugs Market.
Available Customizations:
Global Metastatic Colorectal Cancer Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Global Metastatic Colorectal Cancer Drugs Market Outlook
4.1. Market Size & Forecast
4.1.1. By Value
4.2. Market Share & Forecast
4.2.1. By Drug Class (Anti-EGFR (Epidermal Growth Factor Receptor) Inhibitors, Anti-VEGF (Vascular Endothelial Growth Factor) Therapies, Anti-HER2 (Human Epidermal Growth Factor Receptor 2) Therapies, Immune Checkpoint Inhibitors, Others)
4.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
4.2.3. By Region
4.2.4. By Company (2024)
4.3. Market Map
4.3.1. By Drug Class
4.3.2. By Distribution Channel
4.3.3. By Region
5. Asia Pacific Metastatic Colorectal Cancer Drugs Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Class
5.2.2. By Distribution Channel
5.2.3. By Country
5.3. Asia Pacific: Country Analysis
5.3.1. China Metastatic Colorectal Cancer Drugs Market Outlook
5.3.1.1. Market Size & Forecast
5.3.1.1.1. By Value
5.3.1.2. Market Share & Forecast
5.3.1.2.1. By Drug Class
5.3.1.2.2. By Distribution Channel
5.3.2. India Metastatic Colorectal Cancer Drugs Market Outlook
5.3.2.1. Market Size & Forecast
5.3.2.1.1. By Value
5.3.2.2. Market Share & Forecast
5.3.2.2.1. By Drug Class
5.3.2.2.2. By Distribution Channel
5.3.3. Australia Metastatic Colorectal Cancer Drugs Market Outlook
5.3.3.1. Market Size & Forecast
5.3.3.1.1. By Value
5.3.3.2. Market Share & Forecast
5.3.3.2.1. By Drug Class
5.3.3.2.2. By Distribution Channel
5.3.4. Japan Metastatic Colorectal Cancer Drugs Market Outlook
5.3.4.1. Market Size & Forecast
5.3.4.1.1. By Value
5.3.4.2. Market Share & Forecast
5.3.4.2.1. By Drug Class
5.3.4.2.2. By Distribution Channel
5.3.5. South Korea Metastatic Colorectal Cancer Drugs Market Outlook
5.3.5.1. Market Size & Forecast
5.3.5.1.1. By Value
5.3.5.2. Market Share & Forecast
5.3.5.2.1. By Drug Class
5.3.5.2.2. By Distribution Channel
6. Europe Metastatic Colorectal Cancer Drugs Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class
6.2.2. By Distribution Channel
6.2.3. By Country
6.3. Europe: Country Analysis
6.3.1. France Metastatic Colorectal Cancer Drugs Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Class
6.3.1.2.2. By Distribution Channel
6.3.2. Germany Metastatic Colorectal Cancer Drugs Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Class
6.3.2.2.2. By Distribution Channel
6.3.3. Spain Metastatic Colorectal Cancer Drugs Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Class
6.3.3.2.2. By Distribution Channel
6.3.4. Italy Metastatic Colorectal Cancer Drugs Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Drug Class
6.3.4.2.2. By Distribution Channel
6.3.5. United Kingdom Metastatic Colorectal Cancer Drugs Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Drug Class
6.3.5.2.2. By Distribution Channel
7. North America Metastatic Colorectal Cancer Drugs Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Class
7.2.2. By Distribution Channel
7.2.3. By Country
7.3. North America: Country Analysis
7.3.1. United States Metastatic Colorectal Cancer Drugs Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Class
7.3.1.2.2. By Distribution Channel
7.3.2. Mexico Metastatic Colorectal Cancer Drugs Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Class
7.3.2.2.2. By Distribution Channel
7.3.3. Canada Metastatic Colorectal Cancer Drugs Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Class
7.3.3.2.2. By Distribution Channel
8. South America Metastatic Colorectal Cancer Drugs Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Class
8.2.2. By Distribution Channel
8.2.3. By Country
8.3. South America: Country Analysis
8.3.1. Brazil Metastatic Colorectal Cancer Drugs Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Class
8.3.1.2.2. By Distribution Channel
8.3.2. Argentina Metastatic Colorectal Cancer Drugs Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Class
8.3.2.2.2. By Distribution Channel
8.3.3. Colombia Metastatic Colorectal Cancer Drugs Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Class
8.3.3.2.2. By Distribution Channel
9. Middle East and Africa Metastatic Colorectal Cancer Drugs Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Class
9.2.2. By Distribution Channel
9.2.3. By Country
9.3. MEA: Country Analysis
9.3.1. South Africa Metastatic Colorectal Cancer Drugs Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Class
9.3.1.2.2. By Distribution Channel
9.3.2. Saudi Arabia Metastatic Colorectal Cancer Drugs Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Class
9.3.2.2.2. By Distribution Channel
9.3.3. UAE Metastatic Colorectal Cancer Drugs Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Class
9.3.3.2.2. By Distribution Channel
9.3.4. Egypt Metastatic Colorectal Cancer Drugs Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Drug Class
9.3.4.2.2. By Distribution Channel
10. Market Dynamics
10.1. Drivers
10.2. Challenges
11. Market Trends & Developments
11.1. Recent Developments
11.2. Product Launches
11.3. Mergers & Acquisitions
12. Global Metastatic Colorectal Cancer Drugs Market: SWOT Analysis
